XALATAN SUMMARY
Latanoprost is a prostaglandin F2(alpha) analogue. Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor.
XALATAN Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
|
NEWS HIGHLIGHTS
Published Studies Related to Xalatan (Latanoprost)
Additive Intraocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% (Cosopt) on Monotherapy With Latanoprost (Xalatan) in Patients With Elevated Intraocular Pressure: A Prospective, 4-week, Open-label, Randomized, Controlled Clinical Trial. [2009.09.02]
PURPOSE: To evaluate the additive effect of dorzolamide/timolol fixed combination in patients under monotherapy with latanoprost... CONCLUSIONS: In our sample, dorzolamide 2%/timolol 0.5% fixed combination as add-on therapy in patients with open-angle glaucoma or ocular hypertension under monotherapy with latanoprost with IOP already in mid-teens levels may further enhance pressure reduction.
Pneumatic trabeculoplasty vs latanoprost as adjunctive therapy to timolol in primary open-angle glaucoma or ocular hypertension. [2009.08]
CONCLUSIONS: In eyes with glaucomatous damage that is not advanced, PNT can reduce the IOP in 60% of the eyes at 1 month, and in 33% of the eyes at 3 months, without significant side-effects. The indications, efficacy and safety of PNT retreatments remain to be investigated. IOP reduction is less and of shorter duration than that obtained by latanoprost adjunctive therapy.
A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma. [2009.06]
BACKGROUND/AIMS: To compare the intraocular pressure (IOP) lowering efficacy and side effects of latanoprost 0.005% and bimatoprost 0.03% in subjects with chronic primary angle closure glaucoma (PACG)... CONCLUSIONS: Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG. Both drugs were well tolerated with mild ocular adverse events.
Efficacy and safety of latanoprost in eyes with uveitic glaucoma. [2009.06]
BACKGROUND: To compare the efficacy and safety of latanoprost against a fixed combination of dorzolamide and timolol in eyes with elevated intraocular pressure (IOP) or glaucoma and anterior or intermediate uveitis... CONCLUSION: Latanoprost is safe and equally effective to a fixed combination of dorzolamide and timolol in the treatment of uveitic glaucoma.
24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. [2009.05]
PURPOSE: To evaluate 24-hr intraocular pressure (IOP) and blood pressure (BP) with timolol or latanoprost/timolol fixed combination (LTFC)... CONCLUSIONS: Neither timolol or evening-dosed LTFC reduced SBP, DBP, MBP, OPP, or increased nocturnal dipping. LTFC was more effective than timolol in decreasing IOP.
Clinical Trials Related to Xalatan (Latanoprost)
A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH). [Completed]
This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in
Japanese patients with POAG or OH, in order to show superiority of Xalacom over Xalatan in
efficacy and similarity of safety between Xalacom and Xalatan.
Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata [Active, not recruiting]
This is a single center, randomized, investigator-masked study to determine the efficacy and
safety of latanaprost and bimatoprost ophthalmic solutions in promoting eyelash growth in
patients who have lost their eyelashes due to alopecia areata. These medications are
FDA-approved as eyedrops for patients with glaucoma who have been noted to grow longer,
darker, and thicker eyelashes with their use. In this study, patients will be asked to apply
these solutions to the affected eyelid margins of one eye with a sterile cotton-tipped
applicator once a day.
Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005% [Completed]
Patients with glaucoma or ocular hypertension currently being treated with latanoprost
0. 005%, and in need of additional IOP lowering will be randomized to receive either
brimonidine 0. 1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost
0. 005%
Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study [Active, not recruiting]
This is a randomized observer-masked cross-over study to compare the intraocular pressure
(IOP) reducing effect of latanoprost with bimatoprost in subjects with chronic angle closure
glaucoma (CACG) with raised IOP. Study subjects will be randomized to receive either
latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be
crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the
medications will be assessed by the reduction in IOP after each medication compared to
baseline. The study will be carried out in at least 2 Singapore hospitals.
24-Hour IOP Control With Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combination in Open-Angle Glaucoma [Completed]
The primary objective of this crossover trial is to compare the 3-month mean 24-hour
intraocular pressure (IOP) control and safety of dorzolamide/timolol fixed combination (DTFC)
given twice daily, versus latanoprost/timolol fixed combination (LTFC) given in the evening
and placebo given in the morning, versus adjunctive therapy with DTFC given twice daily and
latanoprost 0. 005% given once in the evening in open-angle glaucoma patients who are
insufficiently controlled with latanoprost monotherapy.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Xalatan has an overall score of 8. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
| | Xalatan review by 45 year old male patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Considerably Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | glaucoma |
| Dosage & duration: | | 1 drop every night (in 24h) (0,005%) (dosage frequency: once a day) for the period of for the last 10 years |
| Other conditions: | | none |
| Other drugs taken: | | Cosopt (dorzolamide Hydrochloride) | | |
Reported Results |
| Benefits: | | lowering of intraocular pressure /keeping it under control |
| Side effects: | | A slight change in the coulour of the treated eye. |
| Comments: | | My juvenile/pigmentary (open angle) glaucoma was diagnosed when I was 26 in 1989 (my mother also had it). I was prescribed 2 kinds of eye drops which were effective for some time, but after a while, they couldn't control the intraocular pressure in my left eye, so I had to undergo a trabeculectomy in 1992.
Now I put drops only in my right eye (Cosopt 2 times a day and Xalatan once a day before I go to sleep). My eye pressure has been under control ever since. |
|
|
|
Page last updated: 2009-10-20
|
